Recursion Pharmaceuticals (RXRX) Operating Expenses (2020 - 2026)

Recursion Pharmaceuticals' Operating Expenses history runs 7 years deep, the most recent figure standing at $135.0 million for Q1 2026.

• Quarterly Operating Expenses fell 34.51% year-over-year to $135.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $651.7 million (up 2.82% YoY) and the FY2025 annual result came in at $722.8 million, up 34.39% from the prior year.
• Operating Expenses was $135.0 million for Q1 2026 at Recursion Pharmaceuticals, down from $143.9 million in the prior quarter.
• Across five years, Operating Expenses topped out at $206.1 million in Q1 2025 and bottomed at $61.3 million in Q1 2022.
• A 5-year average of $122.1 million and a median of $110.1 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2025 — Operating Expenses jumped 87.15% — and 2026, when it slumped 34.51%.
• Recursion Pharmaceuticals' Operating Expenses stood at $74.7 million in 2022, then soared by 47.1% to $109.8 million in 2023, then soared by 71.47% to $188.3 million in 2024, then fell by 23.6% to $143.9 million in 2025, then slipped by 6.18% to $135.0 million in 2026.
• Business Quant data shows RXRX's Operating Expenses at $135.0 million in Q1 2026, $143.9 million in Q4 2025, and $177.4 million in Q3 2025.